At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
In Brief
A Phase 2 clinical trial evaluating adalimumab for FSGS and 3 related conditions. Completed, enrolled 7 participants across 4 sites.
Detailed Summary
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1). Results may help develop individualized treatment options for future patients with TNF-driven focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartOct 2019
Primary CompletionSep 2023
Study CompletionOct 2023
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartOct 2, 2019
Primary CompletionSep 5, 2023
Study CompletionOct 3, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.0 years ago
Interventions
adalimumabdrug
Adalimumab will be dosed based on weight